VA
HALO icon

Vident Advisory’s Halozyme HALO Stock Holding History

Vident Advisory’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$244K Sell
3,121
-716
-19% -$48.8K ﹤0.01% 1703
2026
Q1 		$248K Buy
+3,837
New +$270K ﹤0.01% 1587

Other funds holding HALO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Vident Advisory's HALO Position: Q2 2026 in Review

Vident Advisory reduced its Halozyme (HALO) stake by 19% in Q2 2026, selling an estimated $48.8K and leaving 3,121 shares worth $244K. The position accounts for ﹤0.01% of the portfolio, ranked #1703.

Vident Advisory first reported a position in HALO in Q1 2026 and has held it in 2 quarters since. The position peaked at $248K in Q1 2026. 674 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Vident Advisory held 3,121 shares of Halozyme worth $244K as of Q2 2026.
  • Vident Advisory sold 716 Halozyme shares in Q2 2026, an estimated $48.8K.
  • Halozyme made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1703 holding.
  • Vident Advisory first reported a position in Halozyme in Q1 2026 and has held it in 2 quarters since.
  • Vident Advisory's Halozyme position peaked at $248K in Q1 2026.
  • 674 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.